Additional file 1 of Oral supplementation with fish cartilage hydrolysate in an adult population suffering from knee pain and function discomfort: results from an innovative approach combining an exploratory clinical study and an ex vivo clinical investigation
Creators: name: Yves, Henrotin
name: Herman, Julie
name: Uebelhoer, Melanie
name: Wauquier, Fabien
name: Boutin-Wittrant, Line
name: Donneau, Anne-Françoise
name: Monseur, Justine
name: Fotso, Variance Mokam
name: Duquenne, Marie
name: Wagner, Mélanie
name: Bouvret, Elodie
name: Costes, Bérénice
name: Wittrant, Yohann
Publisher: name: figshare
Year: 2023
Subjects: subject: Medicine
subject: Neuroscience
subject: Physiology
subject: FOS: Biological sciences
subject: Biotechnology
subject: Ecology
subject: Cancer
subject: Mental Health

description: Figure S1. Mean evolution (± SE) of the KOOS sub-scores over time: (a) KOOS Pain score over time; (b) KOOS Symptoms score over time; (c) KOOS Daily living activities score over time; (d) KOOS Sport and recreation function score over time; (e) Quality of life score over time ? FAS population. ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05; ns, not significant. Figure S2. Mean evolution (± SE) of the SF-36 sub-scores over time: (a) SF-36 Physical functioning over time; (b) SF-36 Role limitations due to physical health over time; (c) SF-36 Energy/Fatigue over time; (d) SF-36 Pain over time; (e) SF-36 General health over time ? FAS population. ***p ≤ 0.001; **p ≤ 0.01; *p ≤ 0.05; ns, not significant. Table S1. Subjects? knee discomfort history description at the inclusion in the study ? FAS population. Table S2. Results of the repeated measures ANOVA models for KOOS global score and each subscale, and mean difference and effect size between baseline and 3 months of follow-up ? PP population ? N=24. Table S3. Results of the repeated measures ANOVA models for SF-36 global score and each subscale ? PP population ? N=24. Table S4. Results of the repeated measures ANOVA models for knee pain at rest and while walking and PGA using VAS scale, and mean difference and effect size between baseline and 3 months of follow-up ? PP population ? N=24. Table S5. Comparison of patients? treatment response between the first and the second follow-up ? PP population ? N=24. Table S6. Results of the comparison between the first and the second follow-up for compliance? FAS population. Table S7. Comparisons of subjects satisfaction between the two follow-up visits ? FAS population. Table S8. Results of the analysis of the time evolution for pain killer use and frequency of intake ? FAS population. Table S9: Listing of AE and SAE by decreasing order of frequency ? Safety population ? N=28 adverse events. Table S10. Distribution of link with FCH and action taken in response to AE ? Safety population ? N=28 adverse events. Table S11. Distribution of subjects at each visit ? Safety population ? N=32 patients. Table S12. Complete list of exclusion criteria. Figure S3. Primary human chondrocytes subjected to ex vivo procedures for validation of cell viability in human serum. Cell viability was measured with an XTT-based assay upon either FCS or human serum incubation (H-NAIVE for human naive serum and H-FCH for human serum enriched with circulating FCH metabolites) for 24 h and 48 h (A and B). Measures were performed in quadruplicates per condition/volunteer (n=10 volunteers). Values are presented as mean ± SD. The differences were considered statistically significant at p &lt; 0.05 with ** for p &lt; 0.01 and **** for p &lt; 0.0001.